Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 12, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,055,000 ordinary shares of 25 pence each.
- Purchase Price: 1,125.49 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.02% of total voting rights).
- Shares in Issue: 5,367,871,012 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,055,000 shares purchased on May 12, 2008. Consequently, the total number of shares in issue was updated to 5,367,871,012. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the updated share count of 5,367,871,012 for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the total treasury holding of 484,194,158 shares, which represents 9.02% of voting rights.
- Note that this filing is a notification of a specific share repurchase event and does not contain quarterly or annual financial results.